drugset
drugset / Trial / NCT07653503

Neoadjuvant Lymph Node Targeted Immunotherapy in Cervical Cancer: a Feasibility Study (NEOLYNC)

NCT07653503 ↗

Phase 1 Recruiting 12 enrolled University Medical Center Groningen
NaSingle-groupOpen-labelTreatment

Summary

We aim to determine feasibility, safety and efficacy of TDLN-targeted immune checkpoint inhibition in different doses (nivolumab) in patients with cervical cancer.

Timeline

Start
2026-01-05
Primary completion
2027-12-01
Completion
2027-12-01

Drugs

EvaluationDrugModalityDoseRoute
Subject Nivolumab Monoclonal antibody 5 mg Subcutaneous
Subject Nivolumab Monoclonal antibody 10 mg Subcutaneous
Subject Nivolumab Monoclonal antibody 15 mg Subcutaneous
Subject Nivolumab Monoclonal antibody 30 mg Subcutaneous

Indications

cervical carcinoma